IPCS INCHEM Home

International Agency for Research on Cancer (IARC) - Summaries & Evaluations

CISPLATIN

VOL.: 26 (1981) (p. 151)

5. Summary of Data Reported and Evaluation

5.1 Experimental data

Cisplatin was tested by intraperitoneal administration in mice, increasing the incidence of lung tumours. When cisplatin was administered intraperitoneally, alternately with croton oil application to the skin, papillomas and carcinomas of the skin were produced, along with small numbers of internal neoplasms.

In mice, high doses of cisplatin can induce embryolethality. The limited data available do not allow an evaluation of the teratogenic potential of the drug.

Cisplatin is a mutagen in bacterial and cultured mammalian cells. It also induces chromosomal aberrations in various cells in culture and in mice in vivo. Additionally, treatment of Syrian hamster embryo cells in culture with the drug resulted in the induction of morphological transformation.

5.2 Human data

Cisplatin has been used since the 1970s primarily in the treatment of testicular and ovarian cancer, often in combination with other antineoplastic drugs.

No data were available to evaluate the teratogenic potential or the mutagenicity or chromosomal effects of cisplatin in humans.

No case report or epidemiological study was available to the Working Group.

5.3 Evaluation

There is limited evidence that cisplatin is carcinogenic in mice. No data from studies in humans were available.

The available data were insufficient for the Working Group to evaluate the carcinogenicity of cisplatin to humans.

For definition of the italicized terms, see Preamble Evaluation.

Subsequent evaluation: Suppl. 7 (1987)

Last updated: 8 April 1998 






























    See Also:
       Toxicological Abbreviations
       Cisplatin (PIM 132)
       Cisplatin (UKPID)
       Cisplatin  (IARC Summary & Evaluation, Supplement7, 1987)